Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Relation of pretreatment sequence diversity in NS5A region of HCV genotype 1 with immune response between pegylated-INF/ribavirin therapy outcomes.

Journal of viral hepatitis - 1 Feb 2011

de Queiróz A T L, Maracaja-Coutinho V, Jardim A C G, Rahal P, de Carvalho-Mello I M V G, Matioli S R

Abstract excerpt

Hepatitis C virus (HCV) infection frequently persists despite substantial virus-specific immune responses and the combination of pegylated interferon (INF)-α and ribavirin therapy. Major histocompatibility complex class I restricted CD8(+) T cells are responsible for the control of viraemia in HCV infection, and several studies suggest protection against viral infection associated with specific HLAs. The reason...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Epitopes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to Immune Evasion

Share to Interferons

Share to Ribavirin

Share to Viral Nonstructural Proteins

Source

Identifiers

PMID: 20456637
DOI: 10.1111/j.1365-2893.2010.01294.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Relation of pretreatment sequence diversity in NS5A region of HCV genotype 1 with immune response between pegylated-INF/ribavirin therapy outcomes.PMID 20456637Read ↗

Identification of drug resistance and immune-driven variations in hepatitis C virus (HCV) NS3/4A, NS5A and NS5B regions reveals a new approach toward personalized medicine.Semantic proximity Read ↗

Human leukocyte antigen–associated sequence polymorphisms in hepatitis C virus reveal reproducible immune responses and constraints on viral evolution†Semantic proximity Read ↗

Analysis of HCV quasispecies dynamic under selective pressure of combined therapy.Semantic proximity Read ↗

Bioinformatic analysis of post-transmission viral readaptation in Argentine patients with acute HIV-1 infection.Semantic proximity Read ↗

Computational comparison of availability in CTL/gag epitopes among patients with acute and chronic HIV-1 infection.Semantic proximity Read ↗

Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy.Semantic proximity Read ↗

Prediction of prognostic biomarkers for interferon-based therapy to hepatitis C virus patients: a meta-analysis of the NS5A protein in subtypes 1a, 1b, and 3a.Semantic proximity Read ↗

Phylodynamic Analysis and Implication of HCV Genotype 4 Variability on Antiviral Drug Response and T-Cell Recognition.Semantic proximity Read ↗

Associations between the human MHC and sustained virologic response in the treatment of chronic hepatitis C virus infection.Semantic proximity Read ↗

Combined therapy of interferon plus ribavirin promotes multiple adaptive solutions in hepatitis C virus.Semantic proximity Read ↗

Escape from a dominant HLA-B*15-restricted CD8+ T cell response against hepatitis C virus requires compensatory mutations outside the epitope.Semantic proximity Read ↗

Association between variants in the interferon lambda 4 locus and substitutions in the hepatitis C virus non-structural protein 5A.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.